Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
Sponsor: The Affiliated Hospital of Qingdao University
Summary
This is an investigator-initiated, single-center, open-label study of C-CAR168, an autologous bi-specific CAR-T therapy targeting CD20 and BCMA, for the treatment of adult patients with autoimmune diseases refractory to standard therapy
Official title: An Exploratory Clinical Study of Anti-CD20/B-cell Maturation Antigen (BCMA) Chimeric Antigen Receptor Autologous T Cell Product (C-CAR168) in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
18
Start Date
2026-07
Completion Date
2028-10
Last Updated
2026-06-30
Healthy Volunteers
No
Conditions
Interventions
CD20/BCMA-directed CAR-T cells Autologous 2nd generation
CD20/BCMA-directed CAR-T cells, single infusion intravenously
Locations (1)
The Affiliated Hospital of Qingdao University
Qingdao, Qindao, Shandong, China